Ixchelsis
Ixchelsis develops an oxytocin receptor antagonist for the treatment of premature ejaculation.
Ixchelsis is a company in biotechnology based in Europe, Middle East, and Africa (EMEA), founded in 2011.
As a business in biotechnology, Ixchelsis is listed here with the public details available about it.
Europe, Middle East, and Africa (EMEA) is where the company is located.
Its current recorded stage is Series_Unknown.
Its team size is recorded as c_00001_00010 employees.
It has disclosed roughly $12M in funding.
| Sector | Biotechnology |
|---|---|
| Headquarters | Europe, Middle East, and Africa (EMEA) |
| Founded | 2011 |
| Employees | c_00001_00010 |
| Stage | series_unknown |
| Total funding | $12,000,000 |
Website: ixchelsis.com
Browse related
Full contact details are available to registered Pixilab members.
Create a free account
Create a free account